Averto Medical Inc.
Redwood City, CA
- UEI
- QD1WD56LF265
- CAGE
- 7LG25
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1100 Island Dr #202, Redwood City, CA 94065, USA
- Website
- avertomed.com
- Founded
- 2016
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Eclipse Regenesis, Inc. | Mountain View, CA | — |
| Aspero Medical, Inc. | Westminster, CO | 339112 Surgical and Medical Instrument Manufacturing |
| Medical Device R&D | San Francisco, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Biodevek Inc. | Boston, MA | — |
| Aleo BME Inc. | State College, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Averto Medical Inc. is a for-profit medical device manufacturer headquartered in Fremont, California, focused on developing innovative medical technologies to improve surgical outcomes and patient quality of life. The company specializes in creating minimally invasive medical devices that address critical challenges in colorectal surgery, with a particular emphasis on developing alternatives to traditional temporary ostomy procedures. Registered in SAM.gov since 2016, Averto Medical Inc. has positioned itself as a medical technology innovator targeting significant healthcare challenges in surgical interventions.
Through federal grant awards, Averto Medical Inc. has received substantial funding from multiple federal agencies to advance its medical device technology, primarily the National Cancer Institute, National Science Foundation, and National Institute of Diabetes and Digestive and Kidney Diseases. The company has been awarded multiple grants totaling several million dollars to develop its COLOSEAL ICD System, a proprietary medical device designed to eliminate the need for temporary ostomies in patients undergoing surgeries for conditions like rectal cancer, diverticular disease, and other colorectal diseases. The grants have supported extensive research and development, including safety and efficacy clinical trials, design verification testing, and large animal validation studies. These projects aim to address significant healthcare challenges, with potential market impacts exceeding $10 billion and the ability to reduce surgical complications, healthcare costs, and improve patient quality of life by providing an alternative to traditional temporary ostomy procedures.
Quick answers
Is Averto Medical Inc. registered in SAM.gov?
Yes. Averto Medical Inc.'s SAM.gov registration is active through July 9, 2027.
What is Averto Medical Inc.'s CAGE code?
Averto Medical Inc.'s CAGE code is 7LG25, and its Unique Entity ID (UEI) is QD1WD56LF265.
What is Averto Medical Inc.'s most recent federal award?
Averto Medical Inc.'s most recent federal grant award is Safety and efficacy trial of the coloseal ICD system for the treatment of diverticular disease patients (R44DK143876), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 19, 2025.
On GovTribe
See Averto Medical Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors